Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
June 2019
-
Press Release
Novartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide[1… -
Key Release
Novartis announces new leader of Pharmaceuticals Business Unit
Marie-France Tschudin, an experienced Novartis leader, appointed to President, Novartis Pharmaceuticals Basel, June 7, 2019 - Novartis announced today that Marie-France Tschudin, currently… -
Key Release
Novartis stellt neue Leiterin der Pharmaceuticals Business Unit vor
Marie-France Tschudin, erfahrene Novartis Führungsperson, zur Präsidentin von Novartis Pharmaceuticals ernannt Basel, 7. Juni 2019 - Novartis kündigte heute an, dass Marie-France Tschudin,… -
Press Release
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare®
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare® for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium (177Lu)… -
Press Release
Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible
Data show 60% of iscalimab-treated transplant patients have normal kidney histology at least 1 year after transplant vs 0% with tacrolimus (current standard of care)[1] Less than half of donated… -
Press Release
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®
Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine… -
Story Discovery
Toward improving the health and longevity of transplanted organs
Novartis researchers are working to extend the life of organ transplants
-
Press Release
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (… -
Press Release
Xolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate… -
Press Release
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973)[1] After a median of 42 months follow-up, the survival rate was 70.2% for…
May 2019
-
Press Release
Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
Low dose QMF149 (indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to… -
Story Discovery
Women in Science: Shannon Campbell
How Shannon Campbell, Senior Vice President & Franchise Head at Novartis Oncology, came into her current role and leadership position.